Abstract
A phase II clinical study of intravesical photo dynamic therapy in patients with BCG-unresponsive NMIBC (interim analysis)
Journal of clinical oncology, v 41(6_suppl), pp 528-528
20 Feb 2023
Abstract
528
Background: Novel therapies are required for BCG-unresponsive, high risk non-muscle invasive bladder cancer. We report the interim results of a Phase II Clinical Study of Intravesical Photo Dynamic Therapy (PDT) in patients with BCG-Unresponsive Carcinoma In-Situ (CIS) with or without papillary disease. Methods: Out of a planned 125 patients, 42 patients have been enrolled and treated with two Study Treatments (Day 0 and Day 180) consisting of an intravesical instillation of the photosensitizer TLD-1433 (0.70 mg/cm
2
) followed by activation with a 520 nm intravesical laser under general anesthesia (Study Device TLC-3200) to a total of 90 J/cm2 of laser light. The primary outcome assessed was efficacy, evaluated by Complete Response (CR), at any point in time. The secondary outcome was duration of CR at 12 months, post initial CR. A tertiary objective is safety, evaluated by the incidence and severity of Adverse Events, Grade 4 or higher that do not resolve within 450 days post treatment. Patients with a negative cystoscopy and positive cytology have been defined as indeterminate response (IR), as these patients remain under investigation for lower and upper tract urothelial carcinoma. Results: Interim analyses included the first 42 patients, along with 3 patients treated in a preceding Phase Ib NMIBC clinical study assessing the safety of TLD-1433 PDT who weretreated at the same parameters, for a total of 45 patients. Data for the primary and secondary outcomes are listed in the table.The interim clinical data demonstrates a 90 day CR of 50% and a duration of response at 360 and 450 days of 35% and 21%, respectively.There have been eight Serious Adverse Events (SAE) identified (2 Grade II (tachycardia, hematuria), 3 Grade III (acute kidney injury, cellulitis), 2 Grade IV (urosepsis, depression/anxiety) and 1 Grade V). None of the SAEs were deemed to be directly related to the PDT. Conclusions: The interim data support that treatment with Photo Dynamic Therapy provides a viable treatment option for patients with BCG unresponsive CIS (+/- papillary disease) with an acceptable ongoing safety profile. Clinical trial information: NCT03945162 . [Table: see text]
Metrics
6 Record Views
Details
- Title
- A phase II clinical study of intravesical photo dynamic therapy in patients with BCG-unresponsive NMIBC (interim analysis)
- Creators
- Girish S. Kulkarni - Princess Margaret Cancer CentreKyle A Richards - University of Wisconsin–MadisonPeter C. Black - University of British ColumbiaRicardo A. Rendon - Dalhousie UniversityJoseph Chin - London Health Sciences CentreNeal D. Shore - Carolina Urologic Research CenterGautam Jayram - Urology AssociatesEugene V. Kramolowsky - Urology of VirginiaDaniel Saltzstein - Urology San AntonioPiyush K. Agarwal - University of Chicago Medical CenterLaurence Belkoff - Midlantic Urology, Bala Cynwyd, PAMichael A. O'Donnell - University of IowaAshish M. Kamat - The University of Texas MD Anderson Cancer CenterMichael A.S. Jewett - Princess Margaret Cancer CentreDonald L. Lamm - NRG OncologyVictor DeGruttola - Harvard University PressArkady Mandel - Theralase Technologies Inc., Toronto, ON, CanadaRoger Dumoulin-White - Theralase Technologies Inc, Toronto, ON, CanadaWassim Kassouf - McGill University Health Centre
- Publication Details
- Journal of clinical oncology, v 41(6_suppl), pp 528-528
- Number of pages
- 1
- Resource Type
- Abstract
- Language
- English
- Academic Unit
- Surgery
- Other Identifier
- 991021916912304721